Abstract 3905
Background
Loss of caudal-type homeobox transcription factor-2 (CDX-2) expression in colorectal cancers (CRC) has recently been proposed as a predictive biomarker for response to chemotherapy and also prognosis. However, the data on relationship between alterations in CDX-2 expression and clinicopathological variables remain limited. We herein aimed to investigate the clinicopathological factors and prognostic implications associated with loss of CDX-2 expression in CRC patients.
Methods
Immunohistochemistry for CDX-2 expression was performed on formalin-fixed, paraffin-embedded tissue samples from 427 patients with CRC. Correlation between CDX-2 expression and clinicopathological characteristics were evaluated. Univariate and multivariate survival analyses were performed to reveal the prognostic value of loss of CDX-2 expression.
Results
Of 427 patients, 85% were stage I-III. Seventy six percent had left-sided primary tumors. Deficient mismatch repair (dMMR) was found in 12%. CDX-2-negative expression was identified in 18 out of 427 (4.2%) patients. Loss of CDX-2 expression was more commonly found in patient with right-sided tumors rather than left-sided tumors (9.4% vs 2.8% respectively, p = 0.005) and dMMR compared to proficient MMR (11.5% vs 3.3% respectively, p = 0.006). There was no association between CDX-2 expression and sex, stage, histologic subtype, tumor differentiation and lymphovascular/perineural invasion. By univariate analysis, patients with CDX-2 loss of expression had significantly worse overall survival (OS) and disease free survival (DFS) than those with CDX-2 positive expression (median OS 1.6 vs 11.6 months (mo), p < 0.001; median DFS 1.33 mo vs NR, p = 0.003). By multivariate analysis, loss of CDX-2 expression remained a negative prognostic factor for OS (hazard ratio 2.32; 95%CI 1.25-4.28, p = 0.007).
Conclusions
Loss of CDX-2 expression was associated with right-sided tumor and dMMR status. Moreover, loss of CDX-2 expression is a poor prognostic factor for OS, even among patients with dMMR tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of Medicine Siriraj Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5747 - The routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified
Presenter: Fanny Preat
Session: Poster Display session 2
Resources:
Abstract
1837 - Oncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer
Presenter: Kenjiro Jimbo
Session: Poster Display session 2
Resources:
Abstract
4347 - Pneumonitis and fibrosis after breast cancer radiation.
Presenter: Jarle Karlsen
Session: Poster Display session 2
Resources:
Abstract
2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society
Presenter: Sungmin Park
Session: Poster Display session 2
Resources:
Abstract
804 - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer
Presenter: Chang-ik Yoon
Session: Poster Display session 2
Resources:
Abstract
2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe
Presenter: Francesco Giusti
Session: Poster Display session 2
Resources:
Abstract
1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium
Presenter: Didier Verhoeven
Session: Poster Display session 2
Resources:
Abstract
1534 - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: Poster Display session 2
Resources:
Abstract
4363 - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
Presenter: Emilia Montagna
Session: Poster Display session 2
Resources:
Abstract
2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study
Presenter: Idlir Licaj
Session: Poster Display session 2
Resources:
Abstract